Search results
Showing 991 to 1005 of 1561 results for do not do recommendations
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)
Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia with more than 30% bone marrow blasts.
Recommendation ID NG145/1 Question What is the clinical and cost effectiveness of levothyroxine (T4) and liothyronine (T3) combination
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)
Evidence-based recommendations on danicopan (Voydeya) with ravulizumab (Ultomiris) or eculizumab (Soliris) for paroxysmal nocturnal haemoglobinuria in adults with residual haemolytic anaemia.
information on data.gov.uk . Who we are and what we do You can find information about who we are and what we do: on our...
type of surgery you are thinking of choosing. You might also decide that you do not want to try any of these options just yet, and see...
type of surgery you are thinking of choosing. You might also decide that you do not want to try any of these options just yet, and see...
Direct C1 lateral mass screw for cervical spine stabilisation (HTG92)
Evidence-based recommendations on direct C1 lateral mass screw for cervical spine stabilisation. This involves using screws to fix the bones together to treat atlantoaxial fusion in the neck.
View recommendations for HTG92Show all sections
Sections for HTG92
Endoscopic injection of bulking agents for gastro-oesophageal reflux disease (HTG28)
Evidence-based recommendations on endoscopic injection of bulking agents for gastro-oesophageal reflux disease. This involves injecting a filler into the junction using a catheter to make the entry to the stomach narrower, so that the contents of the stomach cannot pass back.
View recommendations for HTG28Show all sections
Sections for HTG28
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)
Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults.
Show all sections
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.
Evidence-based recommendations on AposHealth for knee osteoarthritis.
Radiofrequency ablation for symptomatic interdigital (Morton's) neuroma (HTG394)
Evidence-based recommendations on radiofrequency ablation for symptomatic interdigital (Morton’s) neuroma. This involves using pulses of radiofrequency heat energy to damage the nerve, with the aim of reducing pain.
View recommendations for HTG394Show all sections
Compression products for treating venous leg ulcers: late-stage assessment (HTG758)
Late-stage assessment (LSA) guidance on compression products for treating venous leg ulcers.
View recommendations for HTG758Show all sections
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.